According to FutureWise analysis, the market for Antibody Drug Conjugate is expected to reach US$ 26.68 billion by 2031 at a CAGR of 16.6% over the forecast period of 2023-2031.
Antibody-drug conjugates (ADCs) are specialized biopharmaceutical medications that combine monoclonal antibodies, which specifically recognize surface antigens on tumor cells, with powerful anti-cancer agents connected by a chemical linker. These complex molecules require careful consideration of several components. The choice of an appropriate target, the monoclonal antibody (mAb), the cytotoxic payload, and the method of linking the antibody to the drug are all crucial factors that influence the safety and effectiveness of ADCs. These targeted agents leverage the unique ability of antibodies to precisely identify and differentiate between healthy and cancerous tissues, along with the cell-killing potential of cytotoxic drugs.
Antibodies are glycoproteins generated by the body in response to foreign particles. A monoclonal antibody (mAb) is made by cloning a specific WBC or unique parent cell. Monoclonal antibodies have monovalent affinity, which means they bind to a specific molecular region or part of an antigen known as an epitope or antigenic determinant. Polyclonal antibodies bind to different epitopes produced by various antibody cell lineages. There are five higher animal types of immunoglobulins: IgG, IgM, IgA, IgE, and IgD. IgG is the most prevalent of all. Each IgG molecule consists of four polypeptide chains, including two heavy chains of 50 kDa and two light chains of 25 kDa, held together by four disulfide bridges.
FutureWise Market Research has published a report that provides an insightful analysis of Antibody Drug Conjugate Market trends affecting overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10050%20&type=requestsample
Antibody Drug Conjugate Market Segmentation:
By Type
- Monoclonal Antibodies
- Linker
- Drug/Toxin
- Others
By Application
- Leukemia
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphocytic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Prostate Cancer
- Kidney Cancer
- Pancreas Cancer
- Ovary Cancer
- Glioblastoma
- Lung Cancer
- Colon Cancer
- Breast Cancer
- Skin Cancer
- Solid Tumors
- Multiple Myeloma
- Lymphoma
By Product
- Adcetris
- Kadcyla
- Others
By Technology
- ImmunoGen Technology
- Seattle Genetics Technology
- Immunomedics Technology
- Others
By End User
- Hospitals
- Specialized Cancer Centers
- Academic Research Institutes
- Biopharmaceutical Companies
- Other
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in the Antibody Drug Conjugate Market:
- Seattle Genetics
- ImmunoGen, Inc.
- Roche Holding AG
- Genentech
- Concortis Biotherapeutics
- AGENSYS, INC.
- Antikor
- Immunomedics
- Pfizer Inc.
- Celldex Therapeutics
- Millennium Pharmaceuticals
- AbbVie Inc.
- Bayer HealthCare
- Astellas Pharma/Agensys
- Progenics Pharmaceuticals
- Mersana Therapeutics
- Synthon
- Heidelberg Pharma
- Oxford BioTherapeutics
Buy now the latest version of this report:
https://www.futurewiseresearch.com/checkout.aspx?ReportId=10050&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Related market:
Some of the other related markets that you might be interested in are listed as below:
Polymer Drug Conjugates Market
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
